Ripretinib

본문 바로가기


Home > Product > Ripretinib
Selling leads
Ripretinib
Posting date : Jul 22, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

KIT/PDGFR INHIBITOR(DCC-2618) is an investigational oral kinase conversion control inhibitor currently under development for the treatment of gastrointestinal stromal tumors (GIST) and advanced systemic mablytosis (ASM). Glioma and other solid tumors (KIT) driven by tyrosine protein kinase KIT or platelet-derived growth factor alpha (PDGFRα) kinases (where genetic mutations or alterations of these kinases play a key role in the biology of these tumors that lead to drug resistance and disease progression)


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top